Press Releases

April 9 2014

The House Subcommittee on Capital Markets and Government Sponsored Enterprises held a hearing...

January 30 2014

Patients Should Be Informed if Doctor's Prescription Changed

January 22 2014

BIO and WBBA commend the Washington State House and Senate for continuing to advance...

November 13 2013

The Pennsylvania Senate Public Health and Welfare Committee approved Senate Bill 405, which...

June 7 2013

Oregon Governor John Kitzhaber signed legislation on Thursday, June 6 designed to address the...

June 5 2013

House Bill 365, signed by Governor Rick Scott, contains four of BIO’s five principles on...

June 3 2013

Florida's repeal of the state Renewable Fuel Standard could chill investment, innovation...

April 23 2013

The Biotechnology Industry Organization (BIO) released its “Bioscience Economic...

April 3 2013

The Biotechnology Industry Organization (BIO) and ...

March 21 2013

In statehouses around the country, lawmakers are beginning to address the complexities of...

January 23 2013

Ken Lisaius has been named Vice President of Communications at BIO.

January 17 2012

Bittenbender will spearhead BIO’s engagement in and support of state-level legislative...

October 26 2011

 BIO Commends Governor Nixon and Missouri Legislature for Commitment to Industry

September 28 2011

The Mississippi Biotechnology Association has joined the Council of State Bioscience...

June 8 2011

BIO announces that Governor Pat Quinn has been selected as the 2011 BIO Governor of the Year...

May 4 2011

The Biotechnology Industry Organization (BIO) announced today its selection of Congressman...

January 31 2014
Dear Ms. Badrov:   The Biotechnology Industry Organization (BIO) and the Illinois Biotechnology Industry Organization (iBIO) appreciate this opportunity to comment on the Illinois Department of Healthcare and Family Services (the “Department”) proposed rule to amend 89 Ill. Adm. Code 140 regarding the 340B Drug Discount Program (the “Proposed Rule”).    BIO is the largest trade association to serve and represent the biotechnology industry in the United States and around the globe.  Indeed, BIO represents more than 1,000 biotechnology companies, academic institutions, state biotechnology centers, and related organizations.   BIO members are involved in the research and development of healthcare, agricultural, industrial, and environmental biotechnology products.  In Illinois BIO works in collaboration with iBIO, whose membership includes strong representation from the bio-pharmaceutical sector.  This sector accounts for a large portion of the $98 billion in biotech annual economic output and 369,000 directly and indirectly-created jobs in the state.  
January 31 2014
Dear Ms. Gibson: To Whom It May Concern: The Biotechnology Industry Organization (BIO) appreciates this opportunity to comment on the Texas Health and Human Services Commission (HHSC) proposed rule regarding 340B program reimbursement (the “Proposed Rule”).  BIO is the largest trade association to serve and represent the biotechnology industry in the United States and around the globe.  Indeed, BIO represents more than 1,000 biotechnology companies, academic institutions, state biotechnology centers, and related organizations.   BIO members are involved in the research and development of healthcare, agricultural, industrial, and environmental biotechnology products. 
January 21 2014
BIO's Senior Policy Consultant, Peter Pellerito, testified before the Michigan Legislature's Bioscience Caucus on economic development initiatives that support the growth of the bioscience industry.
May 8 2013
BIO  urges Florida Governor Scott to sign House Bill 365 – a bill related to the substitution of biologic and biosimilar medicines – which recently passed out of the Legislature.
February 1 2013
BIO supports passage of Florida House Bill 365, which provides requirements for pharmacist to dispense substitute biological products that are determined to be interchangeable for prescribed biological product.
April 10 2014
BIO and Delaware Bio commend the Delaware State Senate for unanimously passing legislation yesterday designed to create a pathway for the substitution of interchangeable biologic medicines. 
April 9 2014
The House Subcommittee on Capital Markets and Government Sponsored Enterprises held a hearing titled “Legislative Proposals to Enhance Capital Formation for Small and Emerging Growth Companies.” Brian Hahn, Chief Financial Officer of GlycoMimetics, Inc. presented testimony at the hearing on enhancements to the capital markets that can increase access to investors and decrease unnecessary regulatory burdens for emerging biotech companies trading on the public market.
January 30 2014
Patients Should Be Informed if Doctor's Prescription Changed
January 22 2014
BIO and WBBA commend the Washington State House and Senate for continuing to advance legislation designed to create a pathway for the substitution of interchangeable biologic medicines.
November 13 2013
The Pennsylvania Senate Public Health and Welfare Committee approved Senate Bill 405, which would require a pharmacist to notify the patient and, within 72 hours, the patient’s physician of any biologic product substitution.